Publications by authors named "Sheela Pangeni Pokharel"

Cell signaling pathways are enriched for biological processes crucial for cellular communication, response to external stimuli, and metabolism. Here, a cell signaling-focused CRISPR screen identified cytochrome c oxidase subunit 4 isoform 1 (COX4I1) as a novel vulnerability in acute myeloid leukemia (AML). Depletion of COX4I1 hindered leukemia cell proliferation and impacted in vivo AML progression.

View Article and Find Full Text PDF
Article Synopsis
  • Epigenetic dysregulation is linked to various cancers, particularly leukemias, and the study explores the role of Tudor domains in leukemia progression and treatment.
  • Researchers used a CRISPR screen to find SGF29, a vital part of acetyltransferase complexes, which is important for gene expression and the development of leukemia.
  • The study introduced a new strategy called CRISPR-SADD for drug discovery, helping to identify a promising inhibitor that targets SGF29's Tudor domain and shows effectiveness against leukemia, suggesting broad applicability for future drug development.
View Article and Find Full Text PDF
Article Synopsis
  • The researchers used CRISPR screens to identify critical integrin proteins, ITGAV and ITGB5, that are vital for cancer cell growth in various cancer models.* -
  • They developed a new drug discovery method called CRISPR-TICA, which combines CRISPR gene tiling and computer-aided design to find potential drug candidates like Cpd_AV2, targeting a specific pocket on ITGAV.* -
  • Treatment with Cpd_AV2 leads to the breakdown of the integrin αVβ5 complex and triggers cell death, showcasing a novel therapeutic strategy focused on disrupting integrin signaling.*
View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on the role of Methyltransferase 16 (METTL16) in liver cancer stem cells (CSCs), revealing its significant involvement in the development and maintenance of hepatocellular carcinoma (HCC) while having a lesser effect on normal liver development.
  • - Using various experimental models, the researchers found that depleting METTL16 reduced CSC frequency and hindered HCC initiation and progression, indicating METTL16's essential role in cancer biology.
  • - The research highlights METTL16 as a key regulator of ribosomal RNA maturation and mRNA translation, identifying eIF3a as a target, providing insights for potential therapeutic developments against liver cancer.
View Article and Find Full Text PDF

Epigenetic dysregulation is reported in multiple cancers including Ewing sarcoma (EwS). However, the epigenetic networks underlying the maintenance of oncogenic signaling and therapeutic response remain unclear. Using a series of epigenetics- and complex-focused CRISPR screens, RUVBL1, the ATPase component of NuA4 histone acetyltransferase complex, is identified to be essential for EwS tumor progression.

View Article and Find Full Text PDF
Article Synopsis
  • N-methyladenosine (mA) is a key modification in mammalian mRNAs and is linked to various diseases, including leukemia.
  • Researchers identified METTL16 as a crucial gene for the survival of acute myeloid leukemia (AML) cells, finding it is overexpressed in human AML and especially prevalent in leukemia stem cells.
  • The study reveals that depleting METTL16 hampers AML development and stem cell self-renewal, largely by altering the metabolism of branched-chain amino acids (BCAAs) through the regulation of enzymes BCAT1 and BCAT2, positioning METTL16 as a significant player in leukemia progression.
View Article and Find Full Text PDF

Epigenetic dysregulation of cell cycle is a hallmark of tumorigenesis in multiple cancers, including hepatocellular carcinoma (HCC). Nonetheless, the epigenetic mechanisms underlying the aberrant cell cycle signaling and therapeutic response remain unclear. Here, we used an epigenetics-focused CRISPR interference screen and identified ACTR5 (actin-related protein 5), a component of the INO80 chromatin remodeling complex, to be essential for HCC tumor progression.

View Article and Find Full Text PDF

Unlabelled: The chromatin reader eleven-nineteen leukemia (ENL) has been identified as a critical dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear. We describe a potent and orally bioavailable small-molecule inhibitor of ENL, TDI-11055, which displaces ENL from chromatin by blocking its YEATS domain interaction with acylated histones. Cell lines and primary patient samples carrying MLL rearrangements or NPM1 mutations are responsive to TDI-11055.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of the mA reader YTHDC1 in promoting metastasis in triple negative breast cancer (TNBC) and its impact on gene expression.
  • Researchers utilized various sequencing methods and a mammary fat pad mouse model to show that higher levels of YTHDC1 correlate with poor patient prognosis and increased lung metastasis of TNBC cells.
  • The findings reveal that YTHDC1 is crucial in regulating TGF-β signaling and the expression of the SMAD3 gene, which is linked to cell migration and invasion in TNBC.
View Article and Find Full Text PDF

Targeted protein degradation is a rapidly advancing and expanding therapeutic approach. Drugs that degrade GSPT1 via the CRL4CRBN ubiquitin ligase are a new class of cancer therapy in active clinical development with evidence of activity against acute myeloid leukemia in early-phase trials. However, other than activation of the integrated stress response, the downstream effects of GSPT1 degradation leading to cell death are largely undefined, and no murine models are available to study these agents.

View Article and Find Full Text PDF

RAS mutations prevalent in high-risk leukemia have been linked to relapse and chemotherapy resistance. Efforts to directly target RAS proteins have been largely unsuccessful. However, since RAS-mediated transformation is dependent on signaling through the RAS-related C3 botulinum toxin substrate (RAC) small GTPase, we hypothesized that targeting RAC may be an effective therapeutic approach in RAS mutated tumors.

View Article and Find Full Text PDF

Cytotoxic natural killer cells kill tumors and infected cells. We carried out CRISPR-based gene editing and transcriptional regulation in hard-to-manipulate NK-92 cells. NK-92-based therapies were found to be safe and efficacious in preclinical studies of cancers.

View Article and Find Full Text PDF

Sphingolipids and their metabolic pathways have been implicated in disease development and therapeutic response; however, the detailed mechanisms remain unclear. Using a sphingolipid network focused CRISPR/Cas9 library screen, we identified an endoplasmic reticulum (ER) enzyme, 3-Ketodihydrosphingosine reductase (KDSR), to be essential for leukemia cell maintenance. Loss of KDSR led to apoptosis, cell cycle arrest, and aberrant ER structure.

View Article and Find Full Text PDF

Identification of novel functional domains and characterization of detailed regulatory mechanisms in cancer-driving genes is critical for advanced cancer therapy. To date, CRISPR gene editing has primarily been applied to defining the role of individual genes. Recently, high-density mutagenesis via CRISPR tiling of gene-coding exons has been demonstrated to identify functional regions in genes.

View Article and Find Full Text PDF